Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 72 out of 100. Treatments

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Importance Women represent two-thirds of patients with Alzheimer disease (AD), and sex differences might affect results of randomized clinical trials (RCTs). Data extraction and synthesis The location and date of publication; number, sex, and age of patients enrolled; disease severity; experimental or approved status of the drug; and whether the study included a sex-stratified analysis in the protocol, methods, or results were extracted by 1 reviewer for each article, and the meta-analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline. The proportion of articles that included sex-stratified results and the temporal trends in the reporting of these results were also studied. Results In this review of 56 RCTs for AD involving 39 575 participants, 23 348 women (59.0%) were included. The proportion of women in RCTs of experimental drugs was significantly lower than the proportion of women in the general population with AD in the US (62.1%; difference, -4.56% [95% CI, -6.29% to -2.87%]; P Conclusions and relevance In this systematic review and meta-analysis, the proportion of women in RCTs for AD, although higher than the proportion of men, was significantly lower than that in the general population. Only a small proportion of trials reported sex-stratified results. These findings support strategies to improve diversity in enrollment and data reporting in RCTs for AD.

What this study adds

Evidence grade: High

This is a pooled review of 100 participants. This systematic review of 56 trials found that women were included at a lower proportion than in the general Alzheimer's disease population and that few trials reported sex-stratified results. Reported effect size: 59.0%; 67.3%; 6.9%.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Martinkova, J., Quevenco, F. C., Karcher, H., Ferrari, A., Sandset, E. C., Szoeke, C., et al. (2021). Proportion of Women and Reporting of Outcomes by Sex in Clinical Trials for Alzheimer Disease: A Systematic Review and Meta-analysis. JAMA network open. https://doi.org/10.1001/jamanetworkopen.2021.24124

Vancouver

Martinkova J, Quevenco FC, Karcher H, Ferrari A, Sandset EC, Szoeke C, et al. Proportion of Women and Reporting of Outcomes by Sex in Clinical Trials for Alzheimer Disease: A Systematic Review and Meta-analysis. JAMA network open. 2021. doi:10.1001/jamanetworkopen.2021.24124. PMID: 34515784.

BibTeX

@article{martinkova2021-34515784,
  author  = {Martinkova, J. and Quevenco, F. C. and Karcher, H. and Ferrari, A. and Sandset, E. C. and Szoeke, C. and Hort, J. and Schmidt, R. and others},
  title   = {{Proportion of Women and Reporting of Outcomes by Sex in Clinical Trials for Alzheimer Disease: A Systematic Review and Meta-analysis}},
  journal = {JAMA network open},
  year    = {2021},
  doi     = {10.1001/jamanetworkopen.2021.24124},
  pmid    = {34515784},
  url     = {https://doi.org/10.1001/jamanetworkopen.2021.24124}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

This systematic review of 56 trials found that women were included at a lower proportion than in the general Alzheimer's disease population and that few trials reported sex-stratified results. It concerns trial diversity and reporting, not treatment, cure, or prevention.

Study details

How this study scored 72/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 2 of 4; Study design 12 of 12; Strength of evidence 5 of 5; Peer-review validation 10 of 10; How recent 3 of 5; Sample size 2 of 4; Effect reported 2 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 4 of 7; Citations per year 3 of 5; Impact for its field and year 3 of 6; Cited by studies here 2 of 6; Still being cited 2 of 4; Senior author's track record 2 of 4; Institution's track record 1 of 3; Multicenter collaboration 3 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 72 of 100.72 of 100 points earned28 not earned

Published in a leading specialty journal, and it is a systematic review of all the studies on the question.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (JAMA network open)
Journal's citation record 2 / 4 JAMA Network Open: journal h-index 235 (OpenAlex, 2026-10-29)
Study design 12 / 12 A systematic review of all the studies on the question
Strength of evidence 5 / 5 Rated “high” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 3 / 5 2021 — within 6 year(s) of the newest study here
Sample size 2 / 4 100 participants
Effect reported 2 / 3 Effect reported as a number, without an interval or test
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 A review of other studies — randomization is not credited here
Times cited 4 / 7 Cited 57 times (OpenAlex, 2026-10-10)
Citations per year 3 / 5 8.1 citations a year over 7 year(s) since 2021
Impact for its field and year 3 / 6 Cited 7.5× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 2 / 6 Cited by 3 other studies in this library
Still being cited 2 / 4 Cited 33 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Maria Teresa Ferretti: h-index 30 (OpenAlex, whole career)
Institution's track record 1 / 3 The University of Melbourne: institution h-index 1,342 (OpenAlex)
Multicenter collaboration 3 / 3 OpenAlex lists 10 institution(s) in 5 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 34515784)
Free to read 2 / 2 Free to read
Total 72 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 39.

Later studies that cite this one

3 studies in the alzhub library list this one in their references.

Related studies in Treatments from nearby years

Also in Treatments

187 studies in the library are filed under Treatments with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Treatments hub.

Similar studies

More on Treatments

See all studies in Treatments →